Literature DB >> 5700853

Angiofollicular lymph node hyperplasia.

P J Fitzpatrick, T C Brown.   

Abstract

Entities:  

Mesh：

Year:  1968        PMID： 5700853      PMCID： PMC1945616     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  REACTIVE PSEUDOLYMPHOMA, NODULAR TYPE.

Authors:  P HIRSCH; R LUKES
Journal:  Arch Dermatol       Date:  1965-04

2.  Angiofollicular mediastinal lymph-node hyperplasia resembling thymoma.

Authors:  E G HARRISON; P E BERNATZ
Journal:  Arch Pathol       Date:  1963-03

3.  Localized lymph node hyperplasia in the mediastinum.

Authors:  C D CHIPMAN; F G DOLAN
Journal:  Can Med Assoc J       Date:  1961-04-22       Impact factor: 8.262

4.  Localized mediastinal lymphnode hyperplasia resembling thymoma.

Authors:  B CASTLEMAN; L IVERSON; V P MENENDEZ
Journal:  Cancer       Date:  1956 Jul-Aug       Impact factor: 6.860

5.  Benign lymphoid masses of probable hamartomatous nature. Analysis of 12 cases.

Authors:  R LATTES; M R PACHTER
Journal:  Cancer       Date:  1962 Jan-Feb       Impact factor: 6.860

6.  Pseudolymphomas of the small intestine.

Authors:  D K Weaver; J G Batsakis
Journal:  Am J Gastroenterol       Date:  1965-10       Impact factor: 10.864

7.  Angiofollicular mediastinal lymph node hyperplasia.

Authors:  G W Cates; C L Robinson
Journal:  Can Med Assoc J       Date:  1967-12-16       Impact factor: 8.262

8.  Angiomatous lymphoid hamartoma. Report of five cases with a review of the literature.

Authors:  K S Tung; L J McCormack
Journal:  Cancer       Date:  1967-04       Impact factor: 6.860
  8 in total
  7 in total

1.  Angiofollicular lymph node hyperplasia (Castleman).

Authors:  D Anagnostou; C V Harrison
Journal:  J Clin Pathol       Date:  1972-04       Impact factor: 3.411

Review 2.  Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature.

Authors:  Iris A C de Vries; Marjolein M S van Acht; Thomas B J Demeyere; Marnix L M Lybeert; Jean-Paul de Zoete; Grard A P Nieuwenhuijzen
Journal:  Radiat Oncol       Date:  2010-02-02       Impact factor: 3.481

3.  Cases report of unicentric Castleman's disease: revisit of radiotherapy role.

Authors:  O Kyu Noh; Sang-Wook Lee; Jae Whan Lee; Sang Yoon Kim; Chung Soo Kim; Eun Kyung Choi; Jong Hoon Kim; Seung Do Ahn
Journal:  Radiat Oncol J       Date:  2013-03-31

4.  International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

Authors:  Frits van Rhee; Eric Oksenhendler; Gordan Srkalovic; Peter Voorhees; Megan Lim; Angela Dispenzieri; Makoto Ide; Sophia Parente; Stephen Schey; Matthew Streetly; Raymond Wong; David Wu; Ivan Maillard; Joshua Brandstadter; Nikhil Munshi; Wilbur Bowne; Kojo S Elenitoba-Johnson; Alexander Fössa; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Sheila K Pierson; Amy Greenway; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Amy Chadburn; David C Fajgenbaum
Journal:  Blood Adv       Date:  2020-12-08

Review 5.  Update and new approaches in the treatment of Castleman disease.

Authors:  Kah-Lok Chan; Stephen Lade; H Miles Prince; Simon J Harrison
Journal:  J Blood Med       Date:  2016-08-03

6.  Castleman disease.

Authors:  Ibrahiem Saeed-Abdul-Rahman; Ali M Al-Amri
Journal:  Korean J Hematol       Date:  2012-09-25

Review 7.  Castleman's disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome.

Authors:  Hongbei Wang; Rosemary L Wieczorek; Michael E Zenilman; Fidelina Desoto-Lapaix; Bimal C Ghosh; Wilbur B Bowne
Journal:  World J Surg Oncol       Date:  2007-11-20       Impact factor: 2.754
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.